Clinical Trial

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Recruiting
View on ClinicalTrials.gov →
Summary
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2024-05-02; most recent amendment 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2024-07-08
Trial Details
NCT Number NCT06401421
Lead Sponsor Exact Sciences Corporation
Collaborators: NSABP Foundation Inc
Conditions Breast Cancer
Enrollment 1,800 participants
Start Date 2024-06-07
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-20